BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib

The multikinase inhibitor, sorafenib (Nexavar®, BAY43-9006), which inhibits both the Raf/MEK/ERK pathway and several receptor tyrosine kinases (RTKs), has shown significantly therapeutic benefits in advanced hepatocellular carcinoma (HCC). However, not all HCC patients respond to sorafenib well and...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Wei-Chien, Hsieh, Yi-Ling, Hung, Chao-Ming, Chien, Pei-Hsuan, Chien, Yu-Fong, Chen, Lei-Chin, Tu, Chih-Yen, Chen, Chia-Hung, Hsu, Sheng-Chieh, Lin, Yueh-Ming, Chen, Yun-Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877048/
https://www.ncbi.nlm.nih.gov/pubmed/24391798
http://dx.doi.org/10.1371/journal.pone.0083627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877048/
https://www.ncbi.nlm.nih.gov/pubmed/24391798
http://dx.doi.org/10.1371/journal.pone.0083627

Ejemplares similares